The endothelin (ET) family of isopeptides (ET -1, ET-2, and ET-3) has been implicated in numerous cerebro vascular pathologies, in part due to their potent vasocon strictor capacity (Foley et aI., 1994; Suzuki et aI., 1992; Mirna et aI., 1989; Gotoh et aI., 1991 
The endothelin (ET) family of isopeptides (ET -1, ET-2, and ET-3) has been implicated in numerous cerebro vascular pathologies, in part due to their potent vasocon strictor capacity (Foley et aI., 1994; Suzuki et aI., 1992; Mirna et aI., 1989; Gotoh et aI., 1991) . Topical or intraparenchymal appli cation of exogenous ET -1 is associated with sufficient reduction in cerebral blood tlow to cause irreversible ischemic brain damage (Robinson et aI., 1990 ; Fuxe et of reperfusion and continuing for 6 or 24 hours (n = 41).
Control cats were treated with 0.9% saline by intravenous in fusion throughout reperfusion. There was no difference in in jury volume or neurologic evaluation score in saline-treated cats (n = II; caudate 24 ± 28%, cortical injury 7.5 ± 5% of ipsilateral structure; score 52 ± 8) versus the results in cats treated with Ro 61-1 790 for either 24 hours (n = 6; caudate 22 ± 23%, cortex 6 ± 5%, injury volume of ipsilateral structure; score 55 ± 3) or 6 hours (n = II; caudate 33 ± 30%, cortex 12 ± 14%, injury volume of ipsilateral structure; score 50 ± 10). Mortality was greatest in the 24-hour drug treatment group.
These data suggest that blockade of ET A rcceptor activity is not beneficial to tissue or functional outcomes from experimental stroke in cat. Key Words: Endothelin-Endothelin receptor type A antagonist-Focal ischemia-Middle cerebral artery occlusion-Neuroprotection.
aI., 1992; Macrae et aI., 1993; Sharkey et aI., 1993) . All three isoforms of ET are present in brain (Sakurai et aI., 1992) , and effects are mediated via two receptor sub types, endothelin type A (ETA) and endothelin type B (ET B ) ' The predominant effect of ETA receptor activity is vasoconstriction, whereas ET B receptors appear to me diate vasodilation in the cerebral circulation (Masaki et aI., 1994) . The effect of ET-J on cerebral vessels has been best studied, but results vary with concentration in vivo, presumably reflecting proportionate ETA and ET B receptor activation. Blockade of ETA receptor prevents ET -I-induced vasoconstriction in isolated pial vessels but has little effect on pial arteriolar diameter under physiological conditions (Patel et aI., 1996a) . Endog enous ETs have been implicated in the pathophysiology of cerebral ischemia (Suzuki et aI., 1992; Ziv et aI., 1992; Patel and McCulloch, 1996; Patel et aI., 1996a,b) , hypo thetically by initiating or amplifying postischemic vaso constriction and microvascular dysfunction. However, combined ET A/ET B antagonists do not improve hypoper fusion after global cerebral ischemia (Patel and McCul-loch, 1996) . In contrast, selective blockade of ETA im proves cerebral perfusion as measured by laser-Doppler flowmetry after focal ischemia, enhancing short-term tis sue survival (Patel et al., 1996b) .
In this study, we examined the effect of selective ET A antagonism on histological and functional recovery from middle cerebral artery occlusion (MeAO) in the cat. We employed a novel agent, Ro 61-1790 [5-methylpyridine-2-sulfonic acid-6-(2-hydroxyethoxy)-5-(2-methoxyphen oxy)-2-(2-1H -tetrazo 1-5 -Y 1-pyridin -4-y 1)-pyrimidin -4-ylamide sodium salt (1:2)] at concentrations confirmed in our preparation to have good tissue penetration. We show that although the agent readily inhibits ET -1-induced pial vasoconstriction, there is no benefit in ex perimental stroke. Further, prolonged ETA antagonism can increase stroke mortality.
MATERIALS AND METHODS
The study was conducted in accordance with National Insti tutes of Health guidelines for the use of experimental animals, and the protocols were approved by the Johns Hopkins Uni versity Animal Care and Use Committee. Initial experiments were conducted to determine the pharmacokinetics of Ro 61-1790 in the cat and allowed selection of the optimal dose for a test of drug efficacy in focal cerebral ischemia. In additional experiments, the effect of the drug on pial vessel response to
ET was measured to demonstrate in vivo activity of the drug within the cerebral circulation.
Pharmacokinetics of Ro 61·1790 in cat plasma
Male cats (2.0 to 4.5 kg; n = 3) received a 10-mg/kg intra venous drug bolus over 30 seconds, with subsequent blood sampling (0.8 mL) at 5, IS, 30, 45, 60, 90, 120, and 180 minutes after injection. Ro 61-1790 (Roche, Basel, Switzer land) was quantified in plasma using high-performance thin layer chromatography after protein precipitation. Analysis was carried out on high-performance thin layer chromatography silica 60F254 (20 x 10 cm) plates using an eluent consisting of ethylacetate/methanol/water/diethylamine (70: I 0:20: IS, by volume). Postchromatographic fluorescence enhancement was done by immersion into Triton X-100 in chloroform and /1-hexane, before in situ fluorescence (A emission >400 nm) by means of a thin layer chromatographic scanner. Quantification was based on external standards using peak height. The quan tification limit of the high-performance thin layer chromatog raphy assay for Ro 61-1790 was 0. 1 f.1g/mL of plasma.
Measurement of pial arteriolar caliber
Male cats (2.0 to 4.5 kg; n = 3) were anesthetized with pentobarbital sodium (35 mg/kg intraperitoneally followed by 5-mg/kg/h infusion) and then mechanically ventilated with supplemental oxygen. Skeletal muscle paralysis was produced with pancuronium bromide (0.1 mg/kg). Femoral artery and venous catheters were placed for blood pressure monitoring, arterial blood gas determination, and infusion of drugs. A pa rietal cranial window was constructed as previously described (Hudak et aI., 1989; Clavier et aI., 1994) 
Middle cerebral artery occlusion study
Ro 61-1790 was stored at -80°C as a stock solution of 50 mg/mL in sterile water until the day of each experiment. Stock solution was then diluted into vehicle containing 0.9% NaCI.
The final concentration was adjusted so that the infusion rate was at 4 mLlkg/h. The infusion was changed every 6 hours to ensure stability within the vehicle at room temperature. hours. The second drug-treated group received 10 mg/kg Ro 61-1790 followed by the 4-mg/kg/h infusion for 6 hours. After 6 hours of infusion, the infusion was changed from Ro 61-1790 to 0.9% saline at the same rate. Neurologic outcome scores (Baskin et aI., 1994; Harukuni et aI., 1998) were recorded at 24 hours of reperfusion by an observer who was blinded to treat ment group. Neurologic score was based on level of conscious ness (maximum score of 4 for normal), gait (maximum score of 10 for normal gait), motor function of the forepaw (maximum score of 7 for normal function for each forepaw), motor func tion of the hindpaw (maximum score of 6 for normal function for each hindpaw), circling (maximum score of 5 for no cir cling), sensory function of the forepaw (maximum score of 4 for normal reaction for each forepaw), and sensory functio of the hindpaw (maximum score of 4 for normal reaction for each hindpaw). The maximum overall neurologic assessment score possible was 61.
After completion of the neurologic evaluation, each animal was reanesthetized with halothane and cardiac arrest was in duced with intravenous potassium chloride. The brain was re-moved, sectioned into 12 3-mm-thick coronal sections, and stained with 2,3,5 -triphenyltetrazolium chloride (Sigma Chemical Co., St. Louis, MO, U.S.A.) for evaluation of infarc tion volume (Bederson et aI., 1986; Cole et aI., 1990 ), as pre viously described (Matsumiya et aI., 1990; Takeshima et aI., 1992) .
Statistical analysis
Values are expressed as means ± SD. Statistical comparison to assess changes in measured physiologic variables within groups was performed by repeated measures analysis of vari ance. Comparison of physiologic variables and injury volume among groups was achieved with one-way analysis of variance.
Post hoc analysis was performed with the Newman-Keuls test.
Data for the pial arteriolar diameter were assessed by using analysis of variance followed by Student's t test with Bonfer roni correction for multiple comparisons. Statistical differences were considered significant at P < 0.05.
RESULTS
Mean plasma clearance for Ro 61-1790 (n = 3) was 4.5 ± 1.6 mLlkg/min. Therefore, a maintenance infusion of Ro 61-1790 at 4 mg/kg/h was chosen to achieve a steady-state plasma level of IS f,Lg/mL. We tested this same infusion in the cranial window experiments to con firm that ET -I-induced vasoconstriction was eliminated by systemic Ro 61-1790. Baseline physiological vari ables including mean arterial blood pressure (l0l ± 8 mm Hg), pH (7.43 ± 0), Paco2 (36.9 ± 1 mm Hg), Pao2 (122 ± 2 mm Hg), and brain temperature (38.5 ± O°C) were well controlled during the experimental period. Pial arteriolar diameter decreased from baseline measure ments in response to ET -I superfusion, with values of -19 ± 15% at 5 minutes, -28 ± 13% at 10 minutes, and -33 ± 18% at 15 minutes after infusion. Intravenous adminstration of Ro 61-1790 increased vessel diameter by 28 ± 18 and 34 ± 23% of baseline by 15 and 30 minutes, respectively. Subsequent ET -I superfusion did not produce vasoconstriction when administered after Ro 61-1790 infusion (2 ± 3, 3 ± 5, and 9 ± 10% of baseline diameters at 5, 10, and 15 minutes, respectively).
Middle cerebral artery occlusion experiments
There were no physiologically significant differences between treatment groups in inhaled halothane concen trations (1.9 to 2.2%), body temperature, mean arterial blood pressure, arterial blood gases, or blood glucose concentration during baseline and ischemia. However, mean arterial blood pressure was significantly higher in all groups at 24 hours of reperfusion as compared with baseline (Table 1) . Overall mortality (failure to survive 24 hours of reperfusion) was higher in cats that received 24 hours of RO 61-1790 infusion (5 of 11) than in those that received a 6-hour infusion (3 of 15) and saline (4 of 15). Because mortality was unacceptably high in the 24-hour infusion group, this treatment group was truncated early in the study. Autopsy of these early mortalities indicated gross cerebral edema in each animal, particu larly severe within the hemisphere ipsilateral to MCAO.
Somatosensory evoked potential amplitude was simi larly ablated in all groups during MCAO and during the first 15 minutes of reperfusion. There was no difference in injury volume (Fig. I ) in saline-treated cats (n = 11; caudate 24 ± 28%, cortical injury 7.5 ± 5% of ipsilateral structure) as compared with the 6-hour drug infusion group (n = 11; caudate 33 ± 30%, cortex 12 ± 14%). Similarly, there was no difference in neurological score between groups (52 ± 8 in saline; 50 ± 10 in 6-hour drug treated). In the 24-hour Ro 61-1790 infusion group that was discontinued due to high mortality, histological in jury was not different in the survivors as compared with A mum required treatment effect to be 36% of the ipsilat eral cortex, assuming an unchanged pooled standard de viation. In fact, the cortical infarction volume in the Ro 61-1790-treated cohort (6-hour treatment, n = 11) was 12 ± 14%. the saline or 6-hour treatment groups (n = 6; caudate 22 ± 23%, cortex 6 ± 5%), and neurological score was 55 ± 3. In a previous study using 90 minutes of MCAO in the cat, we reported a significant reduction of infarction volume by the a-receptor ligand 4-phenyl-l-( 4-phenyl butyl)piperidine (Takahashi et aI., 1995) . A statistical difference was apparent when infarction volume was re duced by 51 % in the caudate-putamen (n = 10/ treatment group). In the present study, treatment with Ro 61-1790 numerically increased the damage observed in caudate-putamen and in cortex; however, this result failed to reach statistical significance by analysis of vari ance or by t test. Using the goal of a 50% treatment effect, we examined post hoc the statistical power of our design and sample size of II animals/group. For the caudate-putamen, the power of our hypothesis testing was 0.73, which was more than adequate to establish a lack of difference between drug-treated and control cats. Because of the small size of cortical lesions in the control cohort (7.5 ± 5% of ipsilateral cortex), the ability to detect a 50% reduction of damage was conducted at a lower statistical power (0.38). To observe a significant difference in cortical infarction volume and reject the null hypothesis (power 0.75), we calculated the mini- 
DISCUSSION
The main finding of this study is that postischemic administration of the specific ETA antagonist Ro 61-1790 does not alter histological injury or neurological outcome when assessed at 24 hours after reversible MCAO in cat. Further, prolonged infusion of the antago nist resulted in high mortality, potentially due to en hanced cerebral injury. Ro 61-1790 as administered in the study was biologically active, as indicated by the agent's ability to attenuate the vasoconstrictive effects of local ET -I on nonischemic pial arterioles studied in situ.
Ro 61-1790 is a trifunctionalized heteroarylsulfon amide pyrimidine with high water solubility for paren teral use (Roux et aI., 1997) . It is a competitive ETA antagonist with an affinity for the ETA receptor in the subnanomolar range with I,OOO-foid selectivity for the ETA versus ET B receptor (Roux et aI., 1997) . The com pound has previously been demonstrated to prevent ce rebral vasospasm in the canine model of subarachnoid hemorrhage in a dose-dependent manner (Roux et aI., 1997) . However, efficacy of this class of drugs in ex perimental stroke when administered after the onset of reperfusion has not been previously tested. Because pre vious reports suggest that ETA receptor antagonists must penetrate the blood-brain barrier for efficacy (Edvinsson et aI., 1993; Patel et aI., 1996b) , the pharmacokinetics of the compound were examined in cat plasma. Based on these data, we employed an intravenous drug regimen of 10 mg/kg as a single bolus followed by a continuous infusion of 4 mg/kg/h. This same dose attenuated exog enous ET-I-induced vasoconstriction of nonischemic ar terioles, demonstrating that bioactive amounts of Ro 61-1790 gain access to the adventitial surface of pial arte riolar vessels. Therefore, it seems unlikely that limited drug availability or access to target tissue would explain the compound's lack of efficacy in experimental stroke.
Endothelin, originally isolated from cultured aortic en dothelial cells (Yanagisawa et aI., 1988) , is involved in a wide variety of physiological and pathophysiological events in brain. Numerous studies have provided evi dence for a deleterious role for the ET family in focal (Suzuki et aI., 1992; Gang-Zhi et aI., 1993; Barone et aI., 1994) and global (Ohlstein et aI., 1994) cerebral isch emia and cardiac arrest (Takasu et aI., 1997) . The ability of exogenous ET-l to overwhelm homeostatic mecha nisms that maintain cerebral blood flow, even in the nor mal brain, has attracted interest in its role in influencing postischemic cerebral blood flow (Robinson et aI., 1990; Macrae et aI., 1993; Sharkey et aI., 1993) . Previous stud ies have reported no significant effect of ET receptor antagonists on cerebral arterial or pial arteriolar caliber in nonpathologic conditions in vivo (Foley et aI., 1994; McAuley et aI., 1996; Patel et aI., 1994) , but topical application of ET -1 antagonists increases the caliber of cortical arterioles in vivo in the ischemic penumbra dur ing a focal cerebral ischemic challenge (Patel et aI., 1996b) . Therefore, a therapeutic potential for ET antago nists has been suggested (Ziv et aI., 1992; Rubyani and Polokoff, 1994; Patel et aI., 1996b) , particularly if these agents reduce vasoconstrictive pathology in collateral vessels supplying the tissue at risk.
Several low molecular weight ET-l antagonists with good blood-brain barrier penetration (for example, bosentan, PD155080, and PD 156707) have been studied in focal cerebral ischemia (Patel et aI., 1994 (Patel et aI., , 1996b . Postischemic treatment with the potent and selective ETA antagonist PD 156707 reduced infarction volume at 6 hours of permanent MCAO (Patel et aI., 1996b) . One speculation is that reduced tissue injury is the result of enhanced peri ischemic cerebral perfusion due to antago nism of the ETA receptor-mediated vasoconstriction and perhaps the unmasking of the ET B receptor-mediated va sodilation (Kobari et aI., 1994; Patel et aI., 1996b) . Tatlisumak et al. (1998) have shown with diffusion per fusion imaging during focal ischemia that ET antagonists can protect brain independently of vascular mechanisms. A role for ETs as neuromodulators has been suggested (Berrino et aI., 1994) , but direct effects of ET receptor antagonists on neuronal function are unclear. In contrast, the present results indicate that blocking ET action via the ETA receptor subtype is not efficacious when tissue injury or neurological function is assessed at 24 hours after MCAO. We measured drug clearance from the cen tral systemic circulation and adjusted our drug adminis tration rate to ensure steady-state drug concentration throughout the study infusion period. We do not know the precise concentration gradient in the arterial tree or the drug concentration in the capillary. Ro 61-1790 con centration used in our study blocked ET-induced con striction in pial arterioles down to 30 /-Lm in diameter. Thus, it seems that effective concentrations were pre sented to vascular endothelium to reduce intraischemic or postischemic ET -induced vasoconstriction in large and small resistance vessels. We did not measure cere brospinal fluid drug concentration or brain penetration and so cannot comment on drug effects that potentially rely on parenchymal accumulation.
Differences in the present results and previous studies may reflect differences in ischemic models or our use of a longer window of observation that extends beyond the initial period of acute cerebral edema and brain swelling. Prolonged blockade of ETA receptors increased mortality to an unacceptable level, so the present study was unable to evaluate the possibility that ischemic damage was exacerbated rather than improved. However, this possi bility cannot be excluded. Enhanced mortality from stroke could result if prolonged ETA antagonist treatment amplified ET B receptor-mediated vasodilation, leading to exacerbation of cerebral edema. Alternatively, long du rations of treatment during reperfusion could exert non specific blockade of vasoconstrictor responses, again leading to enhanced hyperemia and edema.
As expected, we observed a brisk and significant va soconstriction in response to ET-I superfusion over pial arterioles, which was lost in the presence of Ro 61-1790. These findings are in agreement with previous reports that local ET -1 application produces strong vasoconstric tion of both pial and basilar arteries in several species (Mirna et aI., 1989; Gotoh et aI., 1991) ; however, ET -1 can act as a dilator at low doses in pial arteries (Armstead et aI., 1989; Faraci, 1989) . Studies examining cerebrovascular effects of in travenous ET antagonists on basal ceerebral blood flow have yielded mixed results. For example, pretreatment with the nonselective ET antagonist bosentan did not alter cerebral blood flow after transient global ischemia in rats (Patel and McCulloch, 1996) . Further, no effect was observed in canine basilar artery caliber as measured angiographically (Gotoh et aI., 199 1) . However, others have demonstrated a dose-dependent reduction in laser Doppler flowmetry (Willette et aI., 1990) . Our study clearly demonstrates that intravenous administration of Ro 61-1790 increases pial vessel diameter. It can be hy pothesized that these differences may be due to (a) a differential effect of ET A antagonists on different vessels or (b) differences in methodology, species, and animal models.
In summary, intravenous administration of the potent and selective ETA antagonist Ro 61-1790 at a dose that attenuates vasoconstrictive pial arteriolar responses to ET-I does not improve brain injury or neurological out come when given to cats at 90 minutes after MCAO and at the onset of reperfusion. The interaction between ET receptor subtypes in the cerebral circulation under physi ological and ischemic conditions requires further inves tigation. 
